Sections
Excerpt
Pharmacotherapy of bipolar disorders is complex and rapidly evolving. Antipsychotics, antidepressants, anxiolytics, and new-generation anticonvulsants are commonly combined with traditional first-line mood stabilizers (lithium, valproate, carbamazepine) in clinical settings (American Psychiatric Association 2002; Ketter 2005; Suppes et al. 2005). Clinicians are challenged with integrating complex data regarding efficacy and adverse-effect profiles with pharmacological properties in efforts to provide safe, effective, state-of-the-art pharmacotherapy for patients with bipolar disorder.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
